Suguru Shirotake

1.5k total citations
89 papers, 1.1k citations indexed

About

Suguru Shirotake is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Suguru Shirotake has authored 89 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 43 papers in Surgery and 32 papers in Oncology. Recurrent topics in Suguru Shirotake's work include Bladder and Urothelial Cancer Treatments (36 papers), Renal cell carcinoma treatment (29 papers) and Urinary and Genital Oncology Studies (25 papers). Suguru Shirotake is often cited by papers focused on Bladder and Urothelial Cancer Treatments (36 papers), Renal cell carcinoma treatment (29 papers) and Urinary and Genital Oncology Studies (25 papers). Suguru Shirotake collaborates with scholars based in Japan, United States and Germany. Suguru Shirotake's co-authors include Mototsugu Oya, Eiji Kikuchi, Takeo Kosaka, Akira Miyajima, Masafumi Oyama, Nobuyuki Tanaka, Yasumasa Miyazaki, Shuji Mikami, Kent Kanao and Yota Yasumizu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Suguru Shirotake

78 papers receiving 1.1k citations

Peers

Countries citing papers authored by Suguru Shirotake

Since Specialization

Citations

This map shows the geographic impact of Suguru Shirotake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suguru Shirotake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suguru Shirotake more than expected).

Fields of papers citing papers by Suguru Shirotake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suguru Shirotake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suguru Shirotake. The network helps show where Suguru Shirotake may publish in the future.

Co-authorship network of co-authors of Suguru Shirotake

This figure shows the co-authorship network connecting the top 25 collaborators of Suguru Shirotake. A scholar is included among the top collaborators of Suguru Shirotake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suguru Shirotake. Suguru Shirotake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Case of Avelumab-Resistant Upper Urothelial Carcinoma Responding to Pembrolizumab 2025 ·Cureus ·(unknown), Suguru Shirotake, Yu Miyama, Takayuki Takahashi, (unknown), Masayuki Hagiwara, (unknown), Masafumi Oyama	0
2	Outcomes of Nivolumab‐Plus‐Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J‐ ENCORE Study 2025 ·International Journal of Urology ·Tomokazu Sazuka, Katsunori Tatsugami, Suguru Shirotake, Shuzo Hamamoto, Masahiro Nozawa, (unknown), Atsushi Mizokami, Tsunenori Kondo, Sei Naito, Takashige Abe, Kojiro Ohba, Go Kimura, (unknown), Katsumi YAMAGUCHI, Hirotsugu Uemura	0
3	Impact of relative dose intensity on efficacy of enfortumab vedotin monotherapy in platinum and ICI resistant metastatic urothelial carcinoma: A multi-institutional real-world analysis. 2025 ·Journal of Clinical Oncology ·(unknown), Yukihiro Kondo, (unknown), (unknown), Nozomi Hayakawa, Daiki Ikarashi, Ryo Yamashita, Suguru Shirotake, Wataru Obara, (unknown)	0
4	Real-world effectiveness and treatment (tx) patterns in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in Japan: Results from the JAVEMACS chart review study. 2025 ·Journal of Clinical Oncology ·Hiroshi Kitamura, Takashi Kobayashi, (unknown), Masaomi Ikeda, Kan Yonemori, Norihiko Kawamura, Atsuko Fujihara, Takashige Abe, (unknown), Kiyohide Fujimoto, Tohru Nakagawa, (unknown), (unknown), Kiyoaki Nishihara, Daiki Ikarashi, Naoya Masumori, (unknown), Masahiro Shono, Suguru Shirotake, (unknown)	1
5	Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective study 2025 ·International Journal of Clinical Oncology ·Daiki Ikarashi, Nozomi Hayakawa, (unknown), (unknown), Yuki Endo, Ryo Yamashita, Suguru Shirotake, Yukihiro Kondo, (unknown), Wataru Obara	0
6	Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma 2025 ·Cancer Immunology Immunotherapy ·(unknown), (unknown), Shintaro Nakano, (unknown), Masayuki Hagiwara, Takayuki Takahashi, (unknown), (unknown), Shiho Ishikawa, Yoshinori Makino, Masafumi Oyama, Suguru Shirotake	0
7	Robot-Assisted Partial Cystectomy Using the “Double Bipolar Method” 2024 ·Cureus ·(unknown), (unknown), Akira Yabuno, Yu Miyama, (unknown), Masayuki Hagiwara, Suguru Shirotake, Masanori Yasuda, Masafumi Oyama	2
8	New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma 2023 ·SHILAP Revista de lepidopterología ·Takafumi Saito, Kent Kanao, (unknown), (unknown), (unknown), Takayuki Takahashi, (unknown), Suguru Shirotake, Koshiro Nishimoto, Ryuichi Mizuno, Masaru Ishida, Satoshi Hara, Mototsugu Oya, Masafumi Oyama	1
9	Test–retest repeatability of quantitative bone SPECT/CT 2021 ·Annals of Nuclear Medicine ·Tomohiko Yamane, Kenji Fukushima, Suguru Shirotake, Koshiro Nishimoto, Takashi Okabe, Masafumi Oyama, Akira Seto, Ichiei Kuji	10
10	A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis‐assisted transurethral resection involving orally administered 5‐aminolevulinic acid 2019 ·SHILAP Revista de lepidopterología ·Keitaro Watanabe, Suguru Shirotake, (unknown), Takayuki Takahashi, Takeshi Yamanaka, (unknown), Takashi Okabe, Gou Kaneko, Katsuhiro Sano, Masanori Yasuda, Kent Kanao, Masafumi Oyama, Koshiro Nishimoto	2
11	Delayed nivolumab‐induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case 2019 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Takashi Okabe, (unknown), Masafumi Oyama, Suguru Shirotake, Koshiro Nishimoto	4
12	Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer 2019 ·SHILAP Revista de lepidopterología ·(unknown), Gou Kaneko, Suguru Shirotake, Yuki Shimada, Shintaro Nakano, Takashi Okabe, Shiho Ishikawa, Masafumi Oyama, Koshiro Nishimoto	19
13	History of Non–Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy 2018 ·Clinical Genitourinary Cancer ·(unknown), (unknown), (unknown), Suguru Shirotake, Yasumasa Miyazaki, (unknown), Gou Kaneko, (unknown), Nobuyuki Tanaka, Takahiro Maeda, (unknown), Masafumi Oyama, Yosuke Nakajima, Satoshi Hara, (unknown), Mototsugu Oya	11
14	Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings 2016 ·Urologic Oncology Seminars and Original Investigations ·Nobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, Keiichi Ito, Yota Yasumizu, (unknown), Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Ken Nakagawa, Tetsuo Momma, Takeshi Masuda, Tomohiko Asano, Masafumi Oyama, Mototsugu Oya	5
15	Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model 2016 ·Urologic Oncology Seminars and Original Investigations ·Nobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, Keiichi Ito, Suguru Shirotake, (unknown), Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Ken Nakagawa, Tetsuo Momma, Takeshi Masuda, Tomohiko Asano, Masafumi Oyama, Mototsugu Oya	24
16	External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study 2015 ·European Urology Focus ·Nobuyuki Tanaka, Ryuichi Mizuno, Keiichi Ito, Suguru Shirotake, Yota Yasumizu, (unknown), Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Ken Nakagawa, Tetsuo Momma, Takeshi Masuda, Tomohiko Asano, Masafumi Oyama, Mototsugu Oya	25
17	A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy 2014 ·Annals of Surgical Oncology ·Nobuyuki Tanaka, Eiji Kikuchi, Kent Kanao, Kazuhiro Matsumoto, Suguru Shirotake, Yasumasa Miyazaki, Hiroaki Kobayashi, Gou Kaneko, Masayuki Hagiwara, Hiroki Ide, Jun Obata, Katsura Hoshino, Nozomi Hayakawa, Takeo Kosaka, Satoshi Hara, Masafumi Oyama, Tetsuo Momma, Yosuke Nakajima, Masahiro Jinzaki, Mototsugu Oya	56
18	The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: A multi-institutional study 2013 ·Urologic Oncology Seminars and Original Investigations ·Nobuyuki Tanaka, Eiji Kikuchi, Kent Kanao, Kazuhiro Matsumoto, Suguru Shirotake, Hiroaki Kobayashi, Yasumasa Miyazaki, Hiroki Ide, Jun Obata, Katsura Hoshino, Nozomi Hayakawa, Takeo Kosaka, Masafumi Oyama, Akira Miyajima, Tetsuo Momma, Ken Nakagawa, Masahiro Jinzaki, Yosuke Nakajima, Mototsugu Oya	38
19	Metastatic Behavior of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: Association with Primary Tumor Location 2013 ·Annals of Surgical Oncology ·Nobuyuki Tanaka, Eiji Kikuchi, Kent Kanao, Kazuhiro Matsumoto, Hiroaki Kobayashi, Hiroki Ide, Yasumasa Miyazaki, Jun Obata, Katsura Hoshino, Suguru Shirotake, Hirotaka Akita, Takeo Kosaka, Akira Miyajima, Tetsuo Momma, Ken Nakagawa, (unknown), Yosuke Nakajima, Masahiro Jinzaki, Mototsugu Oya	37
20	A case of angiomyolipoma of the renal sinus 2011 ·Clinical and Experimental Nephrology ·Suguru Shirotake, Ichiro Yoshimura, Takeo Kosaka, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact